EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Evaluating Diagnostic Technologies for Breast Lesions: A Focused Review of Breast-Specific Gamma Imaging, Magnetic Resonance Imaging, Mammography, and Ultrasound with Molecular Subtype Insights

Reem Kalakattawi, Lena Gowharji, Alaa marzogi, Tahani Alghamdi

Biomedical and Pharmacology Journal · 31.03.2025 · 18 (1) · 483-497

DOI: 10.13005/bpj/3102 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomedical and Pharmacology Journal, online erschienen am 31.03.2025. Verfasst von Reem Kalakattawi und 3 weiteren Autor:innen. Die Arbeit wurde bisher 4-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This systematic review evaluates the diagnostic effectiveness of breast-specific gamma imaging (BSGI), MRI, mammography, and ultrasound in detecting breast lesions and their associations with molecular subtypes. Following PRISMA guidelines, a comprehensive search of PubMed, Embase, and Cochrane databases was conducted for studies published between January 2014 and October 2024. Nine studies met the inclusion criteria, encompassing clinical trials and observational studies that provided data on sensitivity, specificity, and diagnostic accuracy. Methodological quality was assessed using the QUADAS-2 tool, and pooled diagnostic measures were calculated with STATA V.14.0. BSGI demonstrated high diagnostic performance, with a sensitivity of 91.7% and specificity of 80.7%, surpassing mammography (77.3% sensitivity, 74.5% specificity) and ultrasound (82.1% sensitivity, 70.8% specificity). MRI exhibited the highest sensitivity at 92.5% but lower specificity at 69.7%. The diagnostic odds ratio for BSGI was 4.90 (95% CI: 3.12–7.68), emphasizing its role as a valuable adjunct to mammography and MRI, particularly in dense breast tissues and cases of inconclusive findings. The findings highlight the potential of BSGI to improve diagnostic accuracy and assist in identifying molecular subtypes, such as HER2-positive and triple-negative cancers, facilitating more personalized breast cancer treatment strategies. BSGI’s integration into diagnostic workflows offers promising advancements for breast cancer management.

Zitieren

APA

Kalakattawi, R., Gowharji, L., marzogi, A., & Alghamdi, T. (2025). Evaluating Diagnostic Technologies for Breast Lesions: A Focused Review of Breast-Specific Gamma Imaging, Magnetic Resonance Imaging, Mammography, and Ultrasound with Molecular Subtype Insights. Biomedical and Pharmacology Journal, 18(1), 483-497. https://doi.org/10.13005/bpj/3102

Vancouver

Kalakattawi R, Gowharji L, marzogi A, Alghamdi T. Evaluating Diagnostic Technologies for Breast Lesions: A Focused Review of Breast-Specific Gamma Imaging, Magnetic Resonance Imaging, Mammography, and Ultrasound with Molecular Subtype Insights. Biomedical and Pharmacology Journal. 2025;18(1):483-497. doi:10.13005/bpj/3102

BibTeX
@article{Kalakattawi2025,
  author = {Kalakattawi, Reem and Gowharji, Lena and marzogi, Alaa and Alghamdi, Tahani},
  title = {Evaluating Diagnostic Technologies for Breast Lesions: A Focused Review of Breast-Specific Gamma Imaging, Magnetic Resonance Imaging, Mammography, and Ultrasound with Molecular Subtype Insights},
  journal = {Biomedical and Pharmacology Journal},
  year = {2025},
  volume = {18},
  number = {1},
  pages = {483--497},
  doi = {10.13005/bpj/3102}
}
Kostenlos starten →